Prudence Kgagudi
Overview
Explore the profile of Prudence Kgagudi including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
24
Citations
1366
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Brangel P, Tureli S, Muhlemann B, Liechti N, Zysset D, Engler O, et al.
Viruses
. 2025 Jan;
16(12).
PMID: 39772242
Setting up a global SARS-CoV-2 surveillance system requires an understanding of how virus isolation and propagation practices, use of animal or human sera, and different neutralisation assay platforms influence assessment...
2.
Riou C, Bhiman J, Ganga Y, Sawry S, Ayres F, Baguma R, et al.
PLOS Glob Public Health
. 2024 Apr;
4(4):e0002703.
PMID: 38603677
We report the safety and immunogenicity of fractional and full dose Ad26.COV2.S and BNT162b2 in an open label phase 2 trial of participants previously vaccinated with a single dose of...
3.
Vukovich M, Raju N, Kgagudi P, Manamela N, Abu-Shmais A, Gripenstraw K, et al.
J Virol
. 2023 Dec;
98(1):e0147823.
PMID: 38085509
Consistent elicitation of serum antibody responses that neutralize diverse clades of HIV-1 remains a primary goal of HIV-1 vaccine research. Prior work has defined key features of soluble HIV-1 Envelope...
4.
Riou C, Bhiman J, Ganga Y, Sawry S, Ayres F, Baguma R, et al.
medRxiv
. 2023 Dec;
PMID: 38045321
Background: We report the safety and immunogenicity of fractional and full dose Ad26.COV2.S and BNT162b2 in an open label phase 2 trial of participants previously vaccinated with a single dose...
5.
Motsoeneng B, Manamela N, Kaldine H, Kgagudi P, Hermanus T, Ayres F, et al.
Front Immunol
. 2023 Aug;
14:1231276.
PMID: 37600825
The kinetics of Fc-mediated functions following SARS-CoV-2 infection or vaccination in people living with HIV (PLWH) are not known. We compared SARS-CoV-2 spike-specific Fc functions, binding, and neutralization in PLWH...
6.
Mkhize N, Yssel A, Kaldine H, van Dorsten R, Woodward Davis A, Beaume N, et al.
PLoS Pathog
. 2023 Jun;
19(6):e1011469.
PMID: 37384759
The VRC01 Antibody Mediated Prevention (AMP) efficacy trials conducted between 2016 and 2020 showed for the first time that passively administered broadly neutralizing antibodies (bnAbs) could prevent HIV-1 acquisition against...
7.
Bhiman J, Richardson S, Lambson B, Kgagudi P, Mzindle N, Kaldine H, et al.
Sci Rep
. 2023 Jan;
13(1):1222.
PMID: 36681693
The SARS-CoV-2 Omicron (B.1.1.529) Variant of Concern (VOC) and its sub-lineages (including BA.2, BA.4, BA.5, BA.2.12.1) contain spike mutations that confer high level resistance to neutralizing antibodies induced by vaccination...
8.
Richardson S, Kgagudi P, Manamela N, Kaldine H, Venter E, Pillay T, et al.
Cell Rep Med
. 2023 Jan;
4(1):100910.
PMID: 36603577
The severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) Omicron BA.4 and BA.5 variants caused major waves of infections. Here, we assess the sensitivity of BA.4 to binding, neutralization, and antibody-dependent...
9.
Moyo-Gwete T, Scheepers C, Makhado Z, Kgagudi P, Mzindle N, Ziki R, et al.
Sci Rep
. 2022 Oct;
12(1):16473.
PMID: 36182959
Antibodies with the same variable region can exist as multiple isotypes with varying neutralization potencies, though the mechanism for this is not fully defined. We previously isolated an HIV-directed IgA1...
10.
Scheepers C, Kgagudi P, Mzindle N, Gray E, Moyo-Gwete T, Lambson B, et al.
PLoS Pathog
. 2022 Sep;
18(9):e1010450.
PMID: 36054228
Broadly neutralizing antibodies (bNAbs) that target the membrane-proximal external region (MPER) of HIV gp41 envelope, such as 4E10, VRC42.01 and PGZL1, can neutralize >80% of viruses. These three MPER-directed monoclonal...